Zhang Peipei, Liu Xiaojing, Guo Aili, Xiong Jing, Fu Yu, Zou Kaifang
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China.
Dig Dis Sci. 2016 Sep;61(9):2608-18. doi: 10.1007/s10620-016-4136-z. Epub 2016 Apr 7.
B cell-activating factor (BAFF) has been proposed to be a regulator of B cell and T cell immune responses and be associated with inflammatory processes in autoimmunity and B cell malignancies. No study has reported the role of BAFF in inflammatory bowel disease (IBD).
The purpose of this study was to investigate expression and concentrations of BAFF in IBD and determine its value to discriminate patients with IBD.
Seventy-eight ulcerative colitis (UC) patients, 37 Crohn's disease (CD) patients, 12 irritable bowel syndrome (IBS) patients and 44 healthy controls were recruited. We examined serum and faecal BAFF levels using enzyme-linked immunosorbent assay. Intestinal BAFF expression was analysed in biopsies obtained from IBD patients. Intestinal mucosa localization of BAFF was conducted by immunofluorescence.
The median (25th-75th percentile) serum BAFF concentration (pg/ml) was 1430 (1105-1624) in CD patients, 1472 (1018-1772) in UC patients and 977 (482-1345) in healthy controls. Serum BAFF was 64 % sensitive and 93 % specific for identifying active IBD from healthy controls. The BAFF expression was significantly increased in biopsy specimens from IBD patients. Fecal BAFF concentration was 369 (326-493) pg/ml in CD patients, 542 (358-1758) pg/ml in UC patients, 294 (287-299) pg/ml in IBS patients and 295 (284-309) pg/ml in healthy controls. Fecal BAFF was 90 % sensitive and 96 % specific for identifying active IBD from healthy controls and IBS patients.
The novel association between BAFF and IBD seems to identify that BAFF might regulate the inflammatory process in these diseases and it appears to be a potential marker of IBD.
B细胞活化因子（BAFF）被认为是B细胞和T细胞免疫反应的调节因子，与自身免疫性疾病和B细胞恶性肿瘤中的炎症过程相关。尚无研究报道BAFF在炎症性肠病（IBD）中的作用。
本研究旨在调查BAFF在IBD中的表达和浓度，并确定其对IBD患者的鉴别价值。
招募了78例溃疡性结肠炎（UC）患者、37例克罗恩病（CD）患者、12例肠易激综合征（IBS）患者和44例健康对照。我们使用酶联免疫吸附测定法检测血清和粪便中的BAFF水平。对IBD患者的活检组织进行肠道BAFF表达分析。通过免疫荧光法进行BAFF的肠道黏膜定位。
CD患者血清BAFF浓度（pg/ml）的中位数（第25-75百分位数）为1430（1105-1624），UC患者为1472（1018-1772），健康对照为977（482-1345）。血清BAFF对从健康对照中识别活动性IBD的敏感性为64%，特异性为93%。IBD患者活检标本中的BAFF表达显著增加。CD患者粪便BAFF浓度为369（326-493）pg/ml，UC患者为542（358-1758）pg/ml，IBS患者为294（287-299）pg/ml，健康对照为295（284-309）pg/ml。粪便BAFF对从健康对照和IBS患者中识别活动性IBD的敏感性为90%，特异性为96%。
BAFF与IBD之间的新关联似乎表明BAFF可能调节这些疾病中的炎症过程，并且它似乎是IBD的一个潜在标志物。
